Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions (Q37862576)

24 August 2017

1 reference

title

Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions (English)

1 reference

24 August 2017

O Zolk

1

1 reference

24 August 2017

M F Fromm

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

6 April 2011

1 reference

Clinical Pharmacology & Therapeutics

24 August 2017

1 reference

24 August 2017

89

1 reference

24 August 2017

798-805

1 reference

24 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2010.354

24 August 2017

0 references

cites work

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Pharmacogenetics of drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Mechanisms of renal anionic drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Polymorphism in human organic cation transporters and metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Sirolimus for calcineurin inhibitors in organ transplantation: contra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Antiviral drug-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Blood-brain barrier transporters and response to CNS-active drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Importance of P-glycoprotein at blood-tissue barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Drug transporters in the epileptic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Tubular transporters and clearance of adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

7 January 2021

Calcineurin inhibitor nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

7 January 2021

Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

7 January 2021

Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.354

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.354

1 reference

Dimensions Publication ID

24 August 2017

0 references

1 reference